HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Jeffrey L. Port Rafael S. Andrade Robert J. Korst Paul C. Lee Nasser K. Altorki Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Port, J. L. Articles by Altorki, N. K. Search for Related Content PubMed PubMed Citation Articles by Port, J. L. Articles by Altorki, N. K. Related Collections Lung - cancer

J Thorac Cardiovasc Surg 2005;130:1611-1615
© 2005 The American Association for Thoracic Surgery

General Thoracic Surgery

Positron emission tomographic scanning in the diagnosis and staging of non–small cell lung cancer 2 cm in size or less

Department of Cardiothoracic Surgery, Weill-Cornell Medical Center, New York, NY

^_* Address for reprints: Nasser K. Altorki, MD, Department of Cardiothoracic Surgery, Suite M404, Weill Medical College of Cornell University, 525 East 68th St, New York, NY 10021 (Email: nkaltork{at}med.cornell.edu).

OBJECTIVE: Several studies have suggested that positron emission tomography is more accurate than computed tomography for the staging of non–small cell lung cancer and can reduce the rate of unnecessary thoracotomy in patients with potentially resectable disease. However, there are few data on the utility of positron emission tomography in the diagnosis of patients with tumors of 2 cm or less in size.

METHODS: Patients with cT1/cT2 tumors of 2 cm or less in size were retrospectively reviewed. All had a computed tomographic scan, as well as a positron emission tomographic scan on a dedicated scanner, with a standard uptake value reported. A standard uptake value of 2.5 g/mL or greater was considered positive. The results of computed tomography and positron emission tomography were correlated with pathologic results after either resection (n = 60) or mediastinoscopy (n = 4).

RESULTS: Sixty-four patients (38 women; mean age, 66 years) had a mean tumor size of 1.4 cm (range, 0.7-2.0 cm). Forty-three patients had adenocarcinoma, 13 had adenocarcinoma–bronchioloalveolar carcinoma, 5 had squamous cell carcinoma, and 3 had other tumor types. Twenty-nine (45%) tumors had negative positron emission tomographic results. Both tumor size (>1 cm vs 1 cm) and cell type (adenocarcinoma–bronchioloalveolar carcinoma vs all other cell types) were significant predictors of positron emission tomography uptake in the primary tumor (P = .05 and .01, respectively). Nodal metastases were detected pathologically in 11 (17%) patients (5 N1 and 6 N2). Positron emission tomographic sensitivity and specificity for nodal metastases were only 45% and 89%, respectively. There was no statistically demonstrable survival difference between positron emission tomography–positive and positron emission tomography–negative tumors (3-year survival of 87% vs 100%, respectively).

CONCLUSION: Positron emission tomographic scanning has no demonstrable benefit in the diagnosis, staging, or prognosis of patients with tumors of 2 cm or less in size.

This article has been cited by other articles:

				B. D. Kozower, B. F. Meyers, C. E. Reed, D. R. Jones, P. A. Decker, and J. B. Putnam Jr Does Positron Emission Tomography Prevent Nontherapeutic Pulmonary Resections for Clinical Stage IA Lung Cancer? Ann. Thorac. Surg., April 1, 2008; 85(4): 1166 - 1170. [Abstract] [Full Text] [PDF]

				G. Veronesi, M. Bellomi, U. Veronesi, G. Paganelli, P. Maisonneuve, P. Scanagatta, F. Leo, G. Pelosi, L. Travaini, C. Rampinelli, et al. Role of Positron Emission Tomography Scanning in the Management of Lung Nodules Detected at Baseline Computed Tomography Screening Ann. Thorac. Surg., September 1, 2007; 84(3): 959 - 966. [Abstract] [Full Text] [PDF]

				R. J. Downey, T. Akhurst, M. Gonen, B. Park, and V. Rusch Fluorine-18 fluorodeoxyglucose positron emission tomographic maximal standardized uptake value predicts survival independent of clinical but not pathologic TNM staging of resected non-small cell lung cancer J. Thorac. Cardiovasc. Surg., June 1, 2007; 133(6): 1419 - 1427. [Abstract] [Full Text] [PDF]

				P. C. Lee, R. J. Korst, J. L. Port, Y. Kerem, A. L. Kansler, and N. K. Altorki Long-term survival and recurrence in patients with resected non-small cell lung cancer 1 cm or less in size J. Thorac. Cardiovasc. Surg., December 1, 2006; 132(6): 1382 - 1388. [Abstract] [Full Text] [PDF]

				A. H. Khandani and F. C. Detterbeck Positron emission tomographic scanning in the diagnosis and staging of non-small cell lung cancer 2 cm in size or less J. Thorac. Cardiovasc. Surg., July 1, 2006; 132(1): 214 - 215. [Full Text] [PDF]

				D. Lardinois New Horizons in Staging for Non-Small-Cell Lung Cancer J. Clin. Oncol., April 20, 2006; 24(12): 1785 - 1787. [Full Text] [PDF]